retatrutide clinical trials results trial ⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with obesity or “overweight” The results of the drug

The mutant achieved 3.1-fold higher ATP-generating activity and 1.7-fold higher GSH productivity compared with the control strain

They also note that only a small number of genetic variants were available for analysis, meaning larger clinical studies are still required before GLP-1 drugs can be recommended for treating depression or bipolar disorder

CARMELINA investigators

Andreozzi F, Raciti GA, Nigro C, Mannino GC, Procopio T, Davalli AM, et al

Measurement of calcium response Ca 2+ imaging was performed under continuous perfusion of NG neurons with KrebsRinger-Henseleit buffer (Composition in mmol L 1 : NaCl 119, KCl 4.74, CaCl 2 2.54, MgCl 2 1.19, KH 2 PO 4 1.19, NaHCO 3 25, HEPES 10, pH 7.4) at a flow rate of 600 l/min at 37 C

These cell typespecific changes in dopamine receptor expression could explain the lack of significance seen in previous studies that examined PBMCs as a single population and highlights the need for more cell typefocused analyses of dopamine receptor expression and function